Soligenix Inc SNGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SNGX is a good fit for your portfolio.
News
-
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
-
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
-
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
-
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
-
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
-
Soligenix Announces Reverse Stock Split
-
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Trading Information
- Previous Close Price
- $4.45
- Day Range
- $4.22–4.70
- 52-Week Range
- $1.83–32.00
- Bid/Ask
- $4.39 / $4.75
- Market Cap
- $4.47 Mil
- Volume/Avg
- 213,715 / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.37
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.soligenix.com
Valuation
Metric
|
SNGX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.88 |
Price/Sales | 23.37 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
SNGX
|
---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.08 |
Interest Coverage | — |
Quick Ratio
SNGX
Profitability
Metric
|
SNGX
|
---|---|
Return on Assets (Normalized) | −59.45% |
Return on Equity (Normalized) | −323.95% |
Return on Invested Capital (Normalized) | −101.18% |
Return on Assets
SNGX
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Wkxddfqgm | Fwxdq | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Kqfrbjvf | Gqjdxd | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Gjcftyth | Qxjlfd | $118.7 Bil | |||
Moderna Inc
MRNA
| Pwwbpsh | Gkmw | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Btmgrgxq | Hlvwz | $29.7 Bil | |||
argenx SE ADR
ARGX
| Gplbsgrd | Wpxy | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Ydwxdyzw | Cvwx | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Kdjtqlwd | Ctznmb | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Ngnthcdh | Dlbf | $15.0 Bil | |||
Incyte Corp
INCY
| Qhfbnkqt | Lgpgzw | $13.5 Bil |